OmniAb, Inc.

NASDAQ:OABI

Biotechnology

Healthcare
$5.08 +7.88%

+$0.16 today

Market cap
$740.97M
Beta
1.15
P/E (TTM)
-5.2
EPS (TTM)
-$0.42
52W Low $1.30High $2.79

Volume 1.22M

Average 0.67M

OABI Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

OmniAb, Inc.NASDAQ: OABI

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock rises 16.7% from a year ago

Common stock stood at $14K at the end of Q1 FY2026, up 16.7% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +5.3% a year.

Context

  • Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Common stock increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +16.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14K+0.0% QoQ
Last fiscal yearDec 2025
$14K+16.7% YoY
Year agoMar 2025
$12K+16.7% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.7%——
1 year+16.7%——
3-year CAGR+5.3%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
14K USD
Year-over-year change
+16.7%

Common Stock vs competitors

How OABI compares with its peers on the latest reported figures

  • OABI's Mar 2026 common stock of $14K is the lowest of the 4 companies compared; the peer median is $17K.
  • Its year-over-year change of +16.7% is the highest of 4, against a peer median of +0.8%.
  • Common stock amounts to 0.0% of total assets for OABI, versus a peer median of 0.0%.
OABI Competitors Peer median
Common Stock for OABI and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MGNXMacroGenics, Inc.Mar 2026$636K +0.8%+0.9%0.3%
STROSutro Biopharma, Inc.Mar 2026$17K -79.8%-46.3%0.0%
ABSIAbsci CorporationMar 2026$15K +15.4%+18.6%0.0%
OABIOmniAb, Inc.Mar 2026$14K +16.7%+5.3%0.0%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding OABI) $17K+0.8%+0.9%0.0%

Competitors are the stored peer set for OABI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents033.39M16.36M27.6M25.52M
Short-term Investments054.88M70.63M31.84M28.5M
Net Receivables21.14M30.29M3.84M5.27M7.39M
Inventory00000
Other Current Assets1.41M6.4M4.07M3.43M3.93M
Total Current Assets22.54M124.95M94.9M68.14M65.34M
Property, Plant & Equipment (Net)20.13M41.46M38.13M33.28M24.97M
Goodwill83.98M83.98M83.98M83.98M83.98M
Intangible Assets176.32M167.24M155.47M138.06M125.15M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets1.5M3.58M2.75M2.1M1.47M
Total Non-current Assets281.92M296.26M280.32M257.42M235.57M
Total Assets304.47M421.21M375.23M325.56M300.91M
Account Payables2.92M2.97M4.41M2.3M1.88M
Short-term Debt00003.88M
Tax Payables03.49M000
Deferred Revenue10.79M8.21M6.85M2.34M3.16M
Other Current Liabilities4.92M8.18M7.8M6.67M7.34M
Total Current Liabilities20.58M26.02M23.12M15.09M16.25M
Long-term Debt00000
Deferred Tax Liabilities21.96M21.34M11.35M2.31M785K
Deferred Revenue (Non-current)9.23M4.33M862K117K0
Other Non-current Liabilities5.12M4.14M3.23M1.04M393K
Total Non-current Liabilities49.58M53.82M37.52M22.85M17.63M
Total Liabilities70.16M79.84M60.64M37.94M33.89M
Common Stock012K12K12K14K
Retained Earnings011.25M(39.37M)(101.4M)(166.18M)
Accumulated OCI234.31M9K50K27K12K
Other Stockholders Equity234.31M0000
Minority Interest00000
Total Equity234.31M341.37M314.59M287.62M267.03M
Total Debt13.85M25.8M25.56M23.16M20.33M
Net Debt13.85M(7.59M)9.2M(4.43M)(5.19M)

OmniAb, Inc.

NASDAQ:OABI

Intrinsic Alpha fair value

Locked

Current Price

$5.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.